Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshitaka Yasuhara is active.

Publication


Featured researches published by Yoshitaka Yasuhara.


Diabetes | 2009

Overexpression of GPR40 in Pancreatic β-Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic Mice

Kae Nagasumi; Ritsuko Esaki; Kimihiko Iwachidow; Yoshitaka Yasuhara; Kazuhiro Ogi; Hideyuki Tanaka; Mitsugu Nakata; Takashi Yano; Kozo Shimakawa; Shigehisa Taketomi; Koji Takeuchi; Hiroyuki Odaka; Yoshihiko Kaisho

OBJECTIVE GPR40 is a G protein–coupled receptor regulating free fatty acid–induced insulin secretion. We generated transgenic mice overexpressing the hGPR40 gene under control of the mouse insulin II promoter and used them to examine the role of GPR40 in the regulation of insulin secretion and glucose homeostasis. RESEARCH DESIGN AND METHODS Normal (C57BL/6J) and diabetic (KK) mice overexpressing the hGPR40 gene under control of the insulin II promoter were generated, and their glucose metabolism and islet function were analyzed. RESULTS In comparison with nontransgenic littermates, hGPR40 transgenic mice exhibited improved oral glucose tolerance with an increase in insulin secretion. Although islet morphologic analysis showed no obvious differences between hGPR40 transgenic and nontransgenic mice, isolated islets from hGPR40 transgenic mice had enhanced insulin secretion in response to high glucose (16 mmol/l) compared with those from nontransgenic mice, and they both had similar low glucose (3 mmol/l)-stimulated insulin secretion. In addition, hGPR40 transgenic islets significantly increased insulin secretion against a naturally occurring agonist palmitate in the presence of 11 mmol/l glucose. hGPR40 transgenic mice were also found to be resistant to high-fat diet–induced glucose intolerance, and hGPR40 transgenic mice harboring KK background showed augmented insulin secretion and improved oral glucose tolerance compared with nontransgenic littermates. CONCLUSIONS Our results suggest that GPR40 may have a role in regulating glucose-stimulated insulin secretion and plasma glucose levels in vivo and that pharmacological activation of GPR40 may provide a novel insulin secretagogue beneficial for the treatment of type 2 diabetes.


Frontiers in Behavioral Neuroscience | 2011

Relaxin-3-Deficient Mice Showed Slight Alteration in Anxiety-Related Behavior

Yoshihisa Watanabe; Atsushi Tsujimura; Keizo Takao; Kazunori Nishi; Yasuaki Ito; Yoshitaka Yasuhara; Yasuhito Nakatomi; Chihiro Yokoyama; Kenji Fukui; Tsuyoshi Miyakawa; Masaki Tanaka

Relaxin-3 is a neuropeptide belonging to the relaxin/insulin superfamily. Studies using rodents have revealed that relaxin-3 is predominantly expressed in neurons in the nucleus incertus (NI) of the pons, the axons of which project to forebrain regions including the hypothalamus. There is evidence that relaxin-3 is involved in several functions, including food intake and stress responses. In the present study, we generated relaxin-3 gene knockout (KO) mice and examined them using a range of behavioral tests of sensory/motor functions and emotion-related behaviors. The results revealed that relaxin-3 KO mice exhibited normal growth and appearance, and were generally indistinguishable from wild genotype littermates. There was no difference in bodyweight among genotypes until at least 28 weeks after birth. In addition, there were no significant differences between wild-type and KO mice in locomotor activity, social interaction, hot plate test performance, fear conditioning, depression-like behavior, and Y-maze test performance. However, in the elevated plus maze test, KO mice exhibited a robust increase in the tendency to enter open arms, although they exhibited normal performance in a light/dark transition test and showed no difference from wild-type mice in the time spent in central area in the open field test. On the other hand, a significant increase in the acoustic startle response was observed in KO mice. These results indicate that relaxin-3 is slightly involved in the anxiety-related behavior.


Biochimica et Biophysica Acta | 2011

Apelin-transgenic mice exhibit a resistance against diet-induced obesity by increasing vascular mass and mitochondrial biogenesis in skeletal muscle

Toshihiro Yamamoto; Yugo Habata; Yoshio Matsumoto; Yoshitaka Yasuhara; Tadatoshi Hashimoto; Hitomi Hamajyo; Hisashi Anayama; Ryo Fujii; Hiromitsu Fuse; Yasushi Shintani; Masaaki Mori

BACKGROUND Apelin is an endogenous ligand for the G-protein-coupled 7-transmembrane receptor, APJ. The administration of apelin-13, a truncated 13-amino acid apelin peptide, in diet-induced obese mice is reported to result in a decrease in adiposity due to the increase of energy expenditure with an increase in the expression of uncoupling proteins. METHODS We systematically compared the phenotype of human apelin-transgenic (apelin-Tg) mice fed standard or high-fat diets (HFD) with that of non-Tg control mice to clarify the effect of apelin on obesity. The beneficial effects of apelin were evaluated by multiple assay methods including indirect calorimetrical measurements, gene expression analysis, and immunohistochemical staining. RESULTS Apelin-Tg mice inhibited HFD-induced obesity without altering food intake and exhibited increased oxygen consumption and body temperature compared to non-Tg controls. Interestingly, the mRNA expressions of angiopoietin-1 (Ang1), a key molecule for vascular maturation, and its receptor, endothelium-specific receptor tyrosine kinase 2 (Tie2), were significantly upregulated in the skeletal muscle of HFD-fed apelin-Tg mice, and the areas of anti-CD31 antibody-positive endothelial cells also increased. Furthermore, both the aerobic type-I muscle fibre ratio and the DNA copy number of mitochondrial NADH dehydrogenase subunit 1 increased 2.0- and 1.4-fold in skeletal muscle, respectively. CONCLUSIONS These findings suggest that apelin stimulates energy expenditure via increase vascular mass and mitochondrial biogenesis in skeletal muscle. GENERAL SIGNIFICANCE Apelin is a prerequisite factor for anti-obesity by stimulating energy expenditure via regulating homeostatic energy balance.


Diabetes, Obesity and Metabolism | 2013

Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition

K. Matsuda-Nagasumi; R. Takami-Esaki; K. Iwachidow; Yoshitaka Yasuhara; H. Tanaka; K. Ogi; Mitsugu Nakata; Takashi Yano; S. Hinuma; Shigehisa Taketomi; Hiroyuki Odaka; Yoshihiko Kaisho

G protein‐coupled receptor/free fatty acid receptor 1 (GPR40/FFAR1) regulates free fatty acid‐induced insulin secretion. This study has been performed to clarify whether or not loss of GPR40/FFAR1 function exacerbates diabetes, that is, whether GPR40 has an essential physiological role in the development of diabetes or not.


Scientific Reports | 2016

Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice.

Yusuke Moritoh; Masahiro Oka; Yoshitaka Yasuhara; Hiroyuki Hozumi; Kimihiko Iwachidow; Hiromitsu Fuse; Ryuichi Tozawa

Inositol hexakisphosphate kinase 3 (IP6K3) generates inositol pyrophosphates, which regulate diverse cellular functions. However, little is known about its own physiological role. Here, we show the roles of IP6K3 in metabolic regulation. We detected high levels of both mouse and human IP6K3 mRNA in myotubes and muscle tissues. In human myotubes, IP6K3 was upregulated by dexamethasone treatment, which is known to inhibit glucose metabolism. Furthermore, Ip6k3 expression was elevated under diabetic, fasting, and disuse conditions in mouse skeletal muscles. Ip6k3−/− mice demonstrated lower blood glucose, reduced circulating insulin, deceased fat mass, lower body weight, increased plasma lactate, enhanced glucose tolerance, lower glucose during an insulin tolerance test, and reduced muscle Pdk4 expression under normal diet conditions. Notably, Ip6k3 deletion extended animal lifespan with concomitant reduced phosphorylation of S6 ribosomal protein in the heart. In contrast, Ip6k3−/− mice showed unchanged skeletal muscle mass and no resistance to the effects of high fat diet. The current observations suggest novel roles of IP6K3 in cellular regulation, which impact metabolic control and lifespan.


Hepatology Research | 2017

Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice

Shuntarou Tsuchiya; Yuichiro Amano; Osamu Isono; Mayumi Imai; Fumi Shimizu; Mari Asada; Shigemitsu Imai; Ayako Harada; Yoshitaka Yasuhara; Ryuichi Tozawa; Hiroshi Nagabukuro

Low‐density lipoprotein receptor knockout (LDLR‐KO) mice fed a modified choline‐deficient and amino acid‐defined (mCDAA) diet show non‐alcoholic steatohepatitis (NASH)‐like pathophysiology. In order to pharmacologically benchmark this model, effects of pioglitazone (a thiazolidinedione) and candesartan cilexetil (an angiotensin II type 1 receptor blocker) on steatosis and liver fibrosis were examined.


Biochemical and Biophysical Research Communications | 2017

Osborne-Mendel rats simultaneously develop cardiac and renal dysfunction, left atrial thrombosis, peripheral artery occlusion, and ascending aortic dissection

Makoto Asahina; Hideki Matsumoto; Yoshitaka Yasuhara; Noriko Suzuki; Ritsuko Takami; Michiyasu Takeyama; Ryuichi Tozawa

Although chronic kidney disease (CKD) is strongly associated with onsets of cardiovascular disease (CVD), the pathogenic mechanism between these diseases has not been fully understood. To develop and validate new therapeutic strategies for this complication, appropriate experimental models that reflect the complexity of the underlying pathophysiology are needed. The Osborne-Mendel (OM) rat was identified as an atherosclerosis-prone and a premature-death rat strain among 16 inbred rat strains when fed high-cholesterol containing diet. When fed high-cholesterol diet, OM rats showed simultaneous occurrence of aortic aneurysm, aortic dissection, peripheral artery occlusion, and left atrial thrombosis. OM rats had significantly lower max dP/dt and higher min dP/dt than F344 rats did, indicating impaired left ventricle contractility and relaxation. OM rats developed renal dysfunction, showing increased urinary albumin excretion. OM rats also showed mild hypertension, decreased endothelial function, and enhanced coagulation and platelet aggregation, compared with F344 rats. We now report that OM rat would be a novel spontaneous animal model which simultaneously demonstrates cardiac and renal dysfunction, and CVD events. This model could be a useful model for the pre-clinical testing of pharmacological therapies and could provide new insight into potential targets and pathways for the treatment of CKD and CVD.


Biochemical and Biophysical Research Communications | 2005

Loss of lysophospholipase 3 increases atherosclerosis in apolipoprotein E-deficient mice.

Yoshio Taniyama; Hiromitsu Fuse; Tomoko Satomi; Ryuichi Tozawa; Yoshitaka Yasuhara; Kozo Shimakawa; Sachio Shibata; Masahiko Hattori; Mitsugu Nakata; Shigehisa Taketomi


Biochemical and Biophysical Research Communications | 2005

Transgenic rats overexpressing the human MrgX3 gene show cataracts and an abnormal skin phenotype

Yoshihiko Kaisho; Takuya Watanabe; Mitsugu Nakata; Takashi Yano; Yoshitaka Yasuhara; Kozo Shimakawa; Ikuo Mori; Yasufumi Sakura; Yasuko Terao; Hideki Matsui; Shigehisa Taketomi


Archive | 2002

Animal with gene hypoexpression

Tomoko Satomi; Ryuichi Tozawa; Mitsugu Nakata; Yoshitaka Yasuhara; Yoshio Taniyama

Collaboration


Dive into the Yoshitaka Yasuhara's collaboration.

Top Co-Authors

Avatar

Ryuichi Tozawa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Mitsugu Nakata

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Shigehisa Taketomi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hiromitsu Fuse

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kozo Shimakawa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Takashi Yano

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Tomoko Satomi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yoshihiko Kaisho

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yoshio Taniyama

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Ayako Harada

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge